Occupational stress trajectories and metabolic dysfunction-associated steatotic liver disease among female nurses: a prospective Cohort Study

被引:0
|
作者
Luo, Hanxiao [1 ,3 ]
Xing, Linlin [2 ]
Fu, Tongtong [1 ]
Xiao, Shiqi [1 ]
Fan, Ling [1 ,3 ]
机构
[1] China Med Univ, Dept Nursing, Shengjing Hosp, Shenyang, Liaoning, Peoples R China
[2] China Med Univ, Shengjing Hosp, Dept Radiol, Shenyang, Liaoning, Peoples R China
[3] China Med Univ, Dept Nursing, Shenyang, Liaoning, Peoples R China
关键词
Occupational stress; Trajectory; MASLD; Cohort Study; FATTY LIVER; JOB STRAIN; METAANALYSIS; STATEMENT; DIAGNOSIS; HEALTH; RISK;
D O I
10.1186/s12889-024-20742-z
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prominent cause of chronic liver disease, and occupational stress may serve as a potential risk factor. This study aims to assess the association between occupational stress trajectories and incident MASLD among Chinese female nurses. Methods We conducted a prospective longitudinal study using data from the Nurse' Health Cohort Study, involving 1,113 female nurses, free of MASLD at baseline (2018). Occupational stress was measured using the Chinese Nurse Job Stress Scale at four time points. Group-based trajectory modeling was used to identify distinct stress trajectories. Through doctors' diagnoses, we assessed incident MASLD over a subsequent 6-year period from 2019 to 2024. Cox proportional hazards regression models evaluated the association of stress trajectories and MASLD risk, adjusting for demographics, work-related factors, and medical conditions. Results During follow-up, 256 nurses reported incident physician-diagnosed MASLD. Three occupational stress trajectories were identified: moderate decreasing (36.4%), moderate stable (55.9%), and moderate increasing (7.7%). Participants in the moderate increasing stress trajectory had a significantly higher risk of developing MASLD (adjusted HR: 3.14, 95% CI: 2.19-4.49, p < .001) compared to those in the moderate stable trajectory. This association between stress trajectory and MASLD risk was not modified by age or BMI (p(interaction)>0.50). Conclusions and relevance The study concludes that increasing stress levels over time are associated with a higher incidence of MASLD. These findings underscore the importance of stress management interventions in reducing the risk of MASLD progression. Further research is needed to explore the underlying mechanisms and to develop targeted strategies for stress reduction in clinical settings.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [42] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [43] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [44] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [45] Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Han, Eugene
    Lee, Byung-Wan
    Kang, Eun Seok
    Cha, Bong -Soo
    Ahn, Sang Hoon
    Lee, Yong-ho
    Kim, Seung Up
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 152
  • [46] Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study
    Li, Nan
    Liu, Chenbing
    Lu, Zhangfan
    Wu, Wenjian
    Zhang, Feng
    Qiu, Lihong
    Shen, Chao
    Sheng, Di
    Liu, Zhong
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [47] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [48] Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fu, Yu
    Hua, Yuxin
    Alam, Naqash
    Liu, Enqi
    NUTRIENTS, 2024, 16 (18)
  • [49] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [50] Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress
    Du, Kuo
    Wang, Liuyang
    Jun, Ji Hye
    Dutta, Rajesh K.
    Maeso-Diaz, Raquel
    Oh, Seh Hoon
    Ko, Dennis C.
    Diehl, Anna Mae
    NATURE AGING, 2024, 4 (07): : 949 - 968